gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human Fibrinogen,Thrombin

            Therapeutic Area: Hematology Product Name: TachoSil

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Corza

            Deal Size: $407.9 million Upfront Cash: $407.9 million

            Deal Type: Divestment September 16, 2020

            Details:

            Under the terms of the agreement, upon close, Corza Health will acquire the assets and licenses that support the development and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human fibrinogen,Thrombin

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Johnson & Johnson

            Deal Size: $400.0 million Upfront Cash: Undisclosed

            Deal Type: Termination April 10, 2020

            Details:

            In late March, EU antitrust regulators had expressed concern about the deal and opened a full investigation into it.